Moderate or severe COPD exacerbations increased the risk of adverse cardiovascular events, peaking 1-7 days post-exacerbation (HR 15.86; 95% CI 15.17-16.58) compared to pre-exacerbation periods.
Cohort (n=142,787)
Does moderate or severe COPD exacerbation increase the risk of adverse cardiovascular events in patients with COPD?
142,787 patients with COPD (mean age 68.1 years, 48.3% female) followed for a median of 64 months to assess cardiovascular risks after exacerbations.
Moderate or severe COPD exacerbation (exposure period of 12 months following exacerbation)
Time preceding a first exacerbation (reference period)
Composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemiacomposite
Moderate and severe COPD exacerbations are independent risk factors for adverse cardiovascular events, particularly heart failure decompensation, highlighting the need for optimized COPD management to improve CV outcomes.
Hazard Ratio: 15.86 (95% CI 15.17–16.58)
Absolute Event Rate: 95.61% vs 5.43%
OBJECTIVE: To examine the risk of adverse cardiovascular (CV) events following an exacerbation of chronic obstructive pulmonary disease (COPD). METHODS: This retrospective cohort study identified patients with COPD using administrative data from Alberta, Canada from 2014 to 2019. Exposure periods were 12 months following moderate or severe exacerbations; the reference period was time preceding a first exacerbation. The primary outcome was the composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia. Time-dependent Cox regression models estimated covariate-adjusted risks associated with six exposure subperiods following exacerbation. RESULTS: Among 1 42 787 patients (mean age 68.1 years and 51.7% men) 61 981 (43.4%) experienced at least one exacerbation and 34 068 (23.9%) died during median follow-up of 64 months. The primary outcome occurred in 43 564 (30.5%) patients with an incidence rate prior to exacerbation of 5.43 (95% CI 5.36 to 5.50) per 100 person-years. This increased to 95.61 per 100 person-years in the 1-7 days postexacerbation (adjusted HR 15.86, 95% CI 15.17 to 16.58) and remained increased for up to 1 year. The risk of both the composite and individual CV events was increased following either a moderate or a severe exacerbation, though greater and more prolonged following severe exacerbation. The highest magnitude of increased risk was observed for HF decompensation (1-7 days, HR 72.34, 95% CI 64.43 to 81.22). CONCLUSION: Moderate and severe COPD exacerbations are independent risk factors for adverse CV events, especially HF decompensation. The impact of optimising COPD management on CV outcomes should be evaluated.
Building similarity graph...
Analyzing shared references across papers
Loading...
Nathaniel M. Hawkins
Heart Failure & Transplant
Clémentine Nordon
AstraZeneca (United Kingdom)
Kirsty Rhodes
AstraZeneca (Poland)
Heart
University of British Columbia
AstraZeneca (United Kingdom)
Health Economics and Outcomes Research (United Kingdom)
Building similarity graph...
Analyzing shared references across papers
Loading...
Hawkins et al. (Fri,) conducted a cohort in Chronic obstructive pulmonary disease (COPD) (n=142,787). Moderate or severe exacerbation of COPD vs. Time preceding a first exacerbation was evaluated on Composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia (HR 15.86, 95% CI 15.17 to 16.58). Moderate or severe COPD exacerbations increased the risk of adverse cardiovascular events, peaking 1-7 days post-exacerbation (HR 15.86; 95% CI 15.17-16.58) compared to pre-exacerbation periods.
synapsesocial.com/papers/6a28dfbc55207a4168e21302 — DOI: https://doi.org/10.1136/heartjnl-2023-323487